Introduction {#Sec1}
============

The ever-increasing microbial antibiotic resistance leads to ongoing testing of new biologically efficient compounds of either natural or synthetic origin for infectious diseases \[[@CR1]\]. Subsequently, compounds carrying heterocyclic nuclei gained much attention in the growth of novel antimicrobial agents due to their chemotherapeutic significance. Quinazoline nucleus is an exciting molecule with two nitrogen atoms in its structure among the most significant classes of aromatic bicyclic compounds. Quinazoline is one of the most widespread scaffolds among natural and synthetic bioactive compounds. Quinazoline heterocyclic compound resembles both the purine nucleus and the pteridine one and exhibited wide spectrum medicinal values i.e. antihypertensive, antitumor, antiplasmodial, antiviral and anti-inflammatory activities \[[@CR2], [@CR3]\].

Interest in quinazolinones as anticancer agents has further increased since the discovery of raltitrexed (Tomudex^®^) (Fig. [1](#Fig1){ref-type="fig"}) as an antimetabolite drug used in cancer chemotherapy. Quinazolinone derivatives have been reported to have potent anticancer activities viz. aurora kinase inhibitors \[[@CR4]\], α-folate receptor inhibitors \[[@CR5]\], CDK-inhibitors \[[@CR6]\], activin-like kinase (ALK) inhibitors \[[@CR7]\], EGFR inhibitors \[[@CR8]\], topoisomerase inhibitors \[[@CR9]\], pin1 (Protein interaction with NIMA1) inhibitors \[[@CR10]\], T cell proliferation inhibitors on peripheral blood mononuclear cells (PBMC) and jurkat cells \[[@CR11]\] and VEGFR inhibitors \[[@CR12]\].Fig. 1Structure of Raltitrexed (Tomudex)

Molecular docking analyses provide the most comprehensive illustration of the interaction between drug receptors and produced a modern rational approach to drug design \[[@CR13]\]. The RAW 264.7 cells are monocyte/macrophage like cells from the BALB/c mouse modified cell line from Abelson leukemia virus. These cells are defined as a suitable macrophage model. Pinocytosis and phagocytosis can be performed. RAW 264.7 cells raise the production of nitric oxide (NO) at LPS stimulation and improve phagocytosis. In addition, these cells can destroy target cells by cytotoxicity dependent on antibodies \[[@CR14]\]. Macrophages are immune cells found in many distinct tissues, performing a broad variety of biological activities. They are highly plastic in their pattern of protein expression and can be activated by a variety of cytokines and pathogen-associated molecules like lipopolysaccharide. The quinazoline and other heterocyclic compounds reported have a mass variety of less than 500 ppm or more \[[@CR15]--[@CR18]\].

Recently Kiruthiga et al. \[[@CR19]\] reported that quinazolinone moiety is (**I**) essential for antimicrobial activity. Rajveer et al. \[[@CR20]\] found that acetamide nucleus attached at *N*-1 position to quinazoline moiety (**II**) possessed good antimicrobial activity. Rajasekaran et al. \[[@CR1]\] proposed that acetamide group of quinazolinone moiety (**III**) attached with heterocyclic compound showed better antimicrobial activity. Kumar et al. \[[@CR21]\] found that halogenated phenyl moiety (chlorine substitution at the 2nd position) (**IV**) attached at 2nd position on the quinazolinone nucleus possesses a good antimicrobial activity. Desai et al. \[[@CR3]\] showed that quinazolinones bearing piperazine moiety (**V**) having asserted antimicrobial activity.

Hour et al. \[[@CR22]\] identified that the presence of phenyl ring at 2nd position of quinazolinone nucleus (**VI**) improved the anticancer activity. Xia et al. \[[@CR23]\] revealed that substitution with halogens at 4th position on phenyl ring attached at 2nd position of quinazolinone moiety (**VII**) increased anticancer activity. Raghavendra et al. \[[@CR24]\] reported that acetamide group at *N*-1 position of quinazolinone nucleus (**VIII**) enhanced the anticancer activity. Tobe et al. \[[@CR25]\] reported that quinazolinone nucleus having a piperazine ring substitution (**IX**) exerted an anticancer activity by suppression of T cell proliferation (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Design of proposed quinazolinone molecules based on literature

Rational behind the selection of cyclin dependent kinase (CDK8) {#Sec2}
---------------------------------------------------------------

Quinazolin derivatives are protein kinase inhibitors. Protein kinases are the most important class of human enzymes that regulate the sequence of events such as cell cycle progression, cell division and cell proliferation \[[@CR26]\]. Developing new quinazoline derivatives as an anticancer agent is considered a promising area and researchers around the world are continuously exploring this region to generate new drug candidates \[[@CR26]\]. CDK activity is controlled by association with CDK-inhibiting regulatory subunits (cyclines) and proteins, their phosphorylation status and ubiquitin-mediated proteolysis. Since the loss of cell cycle control leading to deregulated cell proliferation is one of cancer's hallmarks, it is anticipated that the inhibition of CDKs will provide an effective tumor growth control strategy and thus impact cancer therapy. Many organisations researched CDK inhibition and used a range of structural templates with different degrees of selectivity and activity \[[@CR27], [@CR28]\].

In the light of above facts and in continuation of our effort to develop novel anticancer and antimicrobial agents \[[@CR29]--[@CR31]\], the present study is aimed to design, molecular docking and synthesize of 2-(4-(2-chloroacetyl)piperazin-1-yl)-*N*-(2-(4-chlorophenyl)-4-oxoquinazolin-3(4*H*)-yl)acetamides as prospective anticancer and antimicrobial agents.

Experimental {#Sec3}
============

Materials and methods {#Sec4}
---------------------

Starting materials were obtained from commercial sources and used without further purification. The microbial strains for the antimicrobial evaluation were obtained from the Microbial Type Culture Collection and Gene Bank MTCC, Chandigarh. Thin layer chromatography (TLC) using commercial silica gel plates (Merck), Silica gel F254 on aluminum sheets, has noted reaction improvements. Infrared (KBr pellets, cm^−1^) spectra were recorded on an Agilent Resolutions Pro FT-IR spectrometer. Melting points were determined in open capillary tubes. Mass spectra were recorded using Waters Micromass Q-Tof micro instrument. ^1^H-NMR (DMSO) and ^13^C--NMR (DMSO) were recorded at 600 MHz and 150 MHz, respectively on Bruker Avance III 600 NMR spectrometer. Perkin--Elmer 2400 C, H and N analyzer used for elemental analysis.

Synthetic procedure for the synthesis of quinazolinone derivatives (1--17) {#Sec5}
--------------------------------------------------------------------------

### *2*-*(4*-*Chlorophenyl)*-*4H*-*benzo\[e\] \[*[@CR1], [@CR3]*\] oxazin*-*4*-*one* (**I**) {#Sec6}

2-Aminobenzoic acid (0.01 mol) was stirred for 3 h at room temperature with 4-chloro benzoyl chloride (0.01 mol) in the presence of pyridine. The resultant mixture was treated with 5% sodium bicarbonate solution to get **I**, which was filtered, dried and recrystallized with ethanol.

### *3*-*Amino*-*2*-*(4*-*chlorophenyl)quinazolin*-*4(3H)*-*one* (**II**) {#Sec7}

2-(4-Chlorophenyl)-4*H*-benzo\[e\] \[[@CR1], [@CR3]\] oxazin-4-one (**I**) (0.01 mol) was reacted with hydrazine hydrate (0.02 mol) in the presence of ethanol and refluxed for 3 h (30 °C) to obtain **II**. The reaction mixture was cooled and the resultant precipitate was filtered off and recrystallized with ethanol \[[@CR32]\].

### *2*-*Chloro*-*N*-*(2*-*(4*-*chlorophenyl)*-*4*-*oxoquinazolin*-*3(4H)*-*yl)acetamide* (**III**) {#Sec8}

A mixture of 3-amino-2-(4-chlorophenyl)quinazolin-4(3*H*)-one (**II**) (0.01 mol) and chloroacetyl chloride (0.01 mol) with a few drops of glacial acetic acid in absolute ethanol (20 mL) was refluxed for 8 h (30 °C). The reaction mixture was then cooled in ice cold water and resultant precipitate of **III** was filtered, washed with water, dried and recrystallized with ethanol.

### *N*-*(2*-*(4*-*Chlorophenyl)*-*4*-*oxoquinazolin*-*3(4H)*-*yl)*-*2*-*(piperazin*-*1*-*yl)acetamide* (**IV**) {#Sec9}

A mixture of 2-chloro-*N*-(2-(4-chlorophenyl)-4-oxoquinazolin-3(4*H*)-yl)acetamide (**III**) (0.01 mol) and piperazine (0.01 mol) with a few drops of glacial acetic acid in absolute ethanol (20 mL) was refluxed for 10 h (40 °C). The reaction mixture was cooled in ice cold water and resultant precipitate of **IV** was filtered, washed with water, dried and recrystallized with ethanol.

### *2*-*(4*-*(2*-*Chloroacetyl)piperazin*-*1*-*yl)*-*N*-*(2*-*(4*-*chlorophenyl)*-*4*-*oxoquinazolin*-*3(4H)*-*l) acetamide* (**V**) {#Sec10}

*N*-(2-(4-Chlorophenyl)-4-oxoquinazolin-3(4*H*)-yl)-2-(piperazin-1-yl)acetamide (**IV**) (0.01 mol) was further treated with chloroacetyl chloride (0.01 mol) in the presence of few drops of glacial acetic acid in absolute ethanol (20 mL) and refluxed for 8 h (30 °C) yielded of **V**. The reaction mixture was then cooled in ice cold water and resultant precipitate was filtered, washed with water, dried and recrystallized with ethanol. 2-(4-(2-Chloroacetyl)piperazin-1-yl)-*N*-(2-(4-chlorophenyl)-4-oxoquinazolin-3(4*H*)-yl)acetamide (**V**) (0.01 mol) was reacted with different corresponding aniline (0.01 mol) with a few drops of glacial acetic acid in absolute ethanol was refluxed for 10 h (40 °C) to synthesize the title compounds (**1**--**17**). The reaction mixture was then cooled in ice cold water and the resultant precipitate was filtered, washed with water, dried and recrystallized with ethanol.

Antimicrobial evaluation (in vitro) {#Sec11}
-----------------------------------

The synthesized derivatives of quinazolinone were tested using ciprofloxacin (antibacterial) and fluconazole (antifungal) as reference drugs for their in vitro antimicrobial potential. The antimicrobial activity towards Gram-positive bacteria: *S. aureus* MTCC3160, *B. subtilis* MTCC441, Gram-negative bacterium: *E. coli* MTCC443 and fungal species: *C. albicans* MTCC227 and *A. niger* MTCC281 was determined by tube dilution method \[[@CR33]\]. To give a concentration of 100 µg/ml, the standard and test samples were dissolved in DMF. Dilutions of test and standard compounds were prepared in double strength nutrient broth I.P. (bacteria) or Sabouraud dextrose broth I.P. (fungi) \[[@CR34]\].

Anticancer evaluation (in vitro) {#Sec12}
--------------------------------

It has been determined the activity of synthesized compounds and control drugs against human colon (HCT116) and cancer cell lines of the mouse monocyte macrophage leukaemic (RAW 264.7). In RPMI 1640 (Sigma) the selected cancer cell strains were developed, supplemented by 10% heat-inactivated bovine fetal serum (FBS) (PAA Laboratories) and 1% penicillin/streptomycin (PAA Laboratories). Cultures were kept at 37 °C in a humidified incubator in an environment of 5% CO~2~. Anticancer activity of synthesized compounds was assessed at distinct concentrations using MTT assay, as Mosmann (1983) explained but with minor alteration after 72 h of incubation. Using a spectrophotometer at 520 nm, assay sheets were read. Data produced were used to determine a dose--response curve from which the concentration of test compounds needed to kill 50% of the cell population (IC~50~) was determined \[[@CR35]\].

Molecular docking {#Sec13}
-----------------

### Target identification {#Sec14}

Kinase inhibitors are extremely efficient in the therapy of cancer, specifically targeting specific mutations that mainly drive tumorigenesis. They are categorized according to their capacity to catalyze ATP terminal phosphate transfer to substrates that usually contain serine, threonine or tyrosine residues \[[@CR36]\]. Cycline-dependent kinases (CDKs) are a family of significant regulatory proteins that regulate different cell activity and are primarily engaged in the cell cycle and transcription. It is not surprising that many diseases, especially cancer, are common in their aberrant activities, given the fundamental biological functions played by CDKs. Different cell cycle proteins such as CDKs and cyclines induce development of the cell cycle as they are the main regulators of the cell cycle. Previous trials have shown that quinazoline derivatives therapy arrests cancer cells in the G2/M stage CDK activity enables the orderly transition between cell cycle stages. Cell cycle progression inhibition and apoptosis are the most prevalent causes of inhibition of cell growth \[[@CR37]\]. The macrophage-like cell line RAW264.7 promotes replication of murine noroviruses as opposed to most other mouse-derived cell cultures and is commonly used for this purpose. In addition, RAW264.7 was discovered to be unique in research of a mouse model of serious respiratory disease for the propagation of the causative agent, pneumonia virus of mice and for the measurement of pro-inflammatory mediators associated with infection \[[@CR38], [@CR39]\].

### Docking {#Sec15}

To investigate the binding mode of synthesized quinazolinone compounds and standard drugs with selected PDB ID for cancer cell lines, molecular docking research was implemented i.e. human colorectal carcinoma and mouse leukaemic monocyte macrophage, was retrieved from protein data bank. GLIDE (Schrodinger 2018-1, maestro *v11.5*) acquired the docking score and targeted the binding site and formed the grid. The active site grid covered the major amino acids that interact with the receptor. Using their specific PDB ID: 5FGK for human colorectal carcinoma and PDB ID: 5JVY for mouse monocyte macrophage (Additional file [1](#MOESM1){ref-type="media"}), the protein's 3-D structure was acquired from the protein database. The protein structure has been prepared using the protein preparation wizard in the Schrodinger maestro *v11.5*. A set of quinazolinone compounds have been selected as ligands for the docking studies and their structures have been drawn using the workspace of the maestro and converted into 3D form \[[@CR40], [@CR41]\].

Results and discussion {#Sec16}
======================

Chemistry {#Sec17}
---------

A new series of quinazoline derivatives was synthesized using synthetic Scheme [1](#Sch1){ref-type="fig"} (**1**--**17**) (Additional file [2](#MOESM2){ref-type="media"}). The physicochemical and spectral characteristics of the synthesized derivatives are presented in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}, respectively. The molecular structures of the quinazoline compounds were confirmed by FT-IR, ^1^H-NMR, ^13^C--NMR, MS and elemental analysis. The IR spectrum of compound showed around 2928--3077 cm^−1^ and 1561--1592 cm^−1^ indicated the presence of C--H and C=C groups, respectively. The presence of C=O group in compounds displayed in the scale of 1665--1727 cm^−1^. The presence of an arylalkyl ether group (Ar-OCH~3~) in synthesized compounds is established by the existence of an IR absorption band around 1195 cm^−1^. The appearance of IR stretching 1591--1636 cm^−1^ in the spectral data of compounds (**1**--**17**) specified the existence of N=CH group. The appearance of IR stretching 1250--1253 cm^−1^ in the spectral data of synthesized compounds specified the existence of C--N group. The proton NMR displayed the multiplet signals between 6.03 and 8.05 δ ppm in the aromatic ring of the synthesized compounds. The compounds exhibited singlet at 8.91 δ ppm due to the existence of N--NH group. Compounds displayed singlet at 2.36--2.38 δ ppm due to the existence of --CH~3~ group. The compounds displayed singlet at 3.71δ ppm due to the existence of OCH~3~ of Ar-OCH~3~. The ^13^C--NMR spectra of aromatic ring exhibited the carbon atoms in the range of 170.9, 164.9, 164.6, 161.3, 151.9, 138.4, 135.8, 135.5, 133.5, 132.3, 129.5, 129.4, 128.0, 127.9, 127.6, 127.4, 126.9, 122.4, 121.7, 120.6, 118.3, 114.6, 58.7, 52.5, 52.4, 52.3, 46.8, 46.7 of the synthesized compounds. The elemental analysis was found within ± 0.4% of the theoretical results of compounds.Scheme 1Synthesis of 2-(4-(2-chloroacetyl)piperazin-1-yl)-*N*-(2-(4-chlorophenyl)-4-oxoquinazolin-3(4*H*)-yl)acetamide derivatives **1**--**17** Table 1The physicochemical properties of the synthesized compoundsCompound no.M. formulaM. W.M. P. (°C)R~f~ value^a^% yield**1.**C~29~H~29~ClN~6~O~3~545.0150--1520.5191.74**2.**C~28~H~26~Cl~2~N~6~O~3~565.5162--1640.5176.90**3.**C~29~H~29~ClN~6~O~3~545.0156--1580.1318.24**4.**C~30~H~31~ClN~6~O~3~559.1162--1640.5353.03**5.**C~28~H~25~Cl~3~N~6~O~3~599.9108--1100.2069.19**6.**C~29~H~28~ClN~7~O~5~590.0126--1280.1981.53**7.**C~28~H~26~ClN~7~O~5~576.0156--1580.5692.64**8.**C~28~H~26~Cl~2~N~6~O~3~565.5128--1300.4377.08**9.**C~29~H~28~ClN~7~O~5~590.0138--1400.1577.04**10.**C~29~H~29~ClN~6~O~4~561.0156--1580.5059.89**11.**C~28~H~26~Cl~2~N~6~O~3~565.5118--1200.3884.18**12.**C~28~H~25~Cl~2~N~7~O~5~610.4110--1120.5777.70**13.**C~28~H~27~ClN~6~O~3~531.0160--1620.4074.43**14.**C~28~H~25~Cl~3~N~6~O~3~599.9120--1220.2949.42**15.**C~28~H~25~Cl~3~N~6~O~3~599.9168--1700.2076.90**16.**C~28~H~26~ClN~7~O~5~576.0122--1240.2485.78**17.**C~28~H~26~ClN~7~O~5~576.0152--1540.3144.61^a^TLC mobile phase: benzene Table 2Spectral characteristics of the synthesized compoundsCompd. no.IUPAC nomenclatureIR (KBr pellets, cm^−1^)^1^H-NMR and ^13^C--NMR (DMSO δ, ppm)C, H, N analysis and MS**1.***N*-(2-(4-Chlorophenyl)-4-oxoquinazolin-3(4H)-yl)-2-(4-(2-(p-tolyl-amino)acetyl)piperazin-1-yl)acetamideIR: 1669 (C=O str., CONH~2~), 3214 (N--H str., 2° NH~2~), 1469 (N--N str.), 1250 (C--N str.), 3067 (C--H str., Ar), 1590 (C=C str., Ar), 1634 (C= N str., Ar), 2920 (C--H str., R-CO--CH~2~), 725 (C--Cl str., Ar--Cl), 2853 (C--H sym str., Ar-CH~3~)^1^H-NMR: 7.38--8.05 (m, 12H, ArH), 8.19 (s, 1H, N--NH), 4.15 (d, 2H, CH~2~), 2.38 (s, 3H CH~3~), 3.32 (t, 4H, CH~2~ of piperazine), 2.63 (t, 4H, CH~2~ of piperazine); ^13^C--NMR: 170.2, 164.6, 164.2, 161.4, 151.7, 149.3, 135.6, 135.4, 133.1, 131.2, 129.3, 129.5, 128.8, 127.4, 127.2, 126.6, 122.5, 120.5, 117.5, 113.6, 111.7, 58.5, 53.5, 52.7, 52.5, 46.9, 46.5Anal cal. C, 63.91; H, 5.36; N, 15.42; Found: C, 63.94; H, 5.32; N, 15.40; MS ES+ (ToF): *m/z* 546 \[M^+^ + 1\]**2.***N*-(2-(4-Chlorophenyl)-4-oxoquinazolin-3(4H)-yl)-2-(4-(2-((3-chloro-phenyl)amino)acetyl)- piperazin-1-yl)acetamideIR: 1668 (C=O str., CONH~2~), 3213 (N--H str., 2° NH~2~), 1468 (N--N str.), 1252 (C--N str.), 3067 (C--H str., Ar), 1591 (C=C str., Ar), 1632 (C= N str., Ar), 2957 (C--H str., R-CO--CH~2~), 1727 (C=O str., Ar-ketone), 726 (C--Cl str., Ar--Cl)^1^H-NMR: 6.55--7.86 (m, 12H, ArH), 8.19 (s, 1H, N--NH), 4.15 (d, 2H, CH~2~), 3.33 (t, 4H, CH~2~ of piperazine), 2.64 (t, 4H, CH~2~ of piperazine); ^13^C--NMR: 170.0, 164.6, 164.3, 161.3, 151.0, 145.5, 135.5, 133.5, 129.9, 129.8, 129.6, 129.5, 128.7, 127.1, 127.2, 127.3, 126.2, 122.7, 122.4, 120.9, 114.6, 58.6, 53.4, 52.1, 52.0, 46.9, 46.7Anal cal. C, 59.47; H, 4.63; N, 14.86; Found: C, 59.49; H, 4.67; N, 14.83; MS ES+ (ToF): *m/z* 566 \[M^+^ + 1\]**3.***N*-(2-(4-Chlorophenyl)-4-oxoquinazolin-3(4H)-yl)-2-(4-(2-(m-tolyl-amino)acetyl)piperazin-1-yl)acetamideIR: 1669 (C=O str., CONH~2~), 3214 (N--H str., 2° NH~2~), 1467 (N--N str.), 1272 (C--N str.), 3068 (C--H str., Ar), 1592 (C=C str., Ar), 1632 (C= N str., Ar), 2958 (C--H str., R-CO--CH~2~), 1726 (C=O str., Ar-ketone), 727 (C--Cl str., Ar--Cl), 2863 (C--H sym str., Ar-CH~3~)^1^H-NMR: 7.00--7.74 (m, 11H, ArH), 8.19 (s, 1H, N--NH), 4.15 (d, 2H, CH~2~), 3.34 (t, 4H, CH~2~ of piperazine), 2.63 (t, 4H, CH~2~ of piperazine), 2.36 (s, 3H, CH~3~); ^13^C--NMR: 170.2, 164.7, 164.6, 161.0, 151.1, 136.7, 136.6, 135.3, 133.4, 129.6, 129.2, 128.6, 127.4, 127.2, 127.1, 127.0, 126.1, 122.0, 120.7, 116.5, 114.4, 114.0, 58.8, 53.6, 52.4, 52.3, 46.8, 46.7, 15.6Anal cal. C, 63.91; H, 5.36; N, 15.42; Found: C, 63.95; H, 5.40; N, 15.48; MS ES+ (ToF): *m/z* 545 \[M^+^ + 1\]**4.***N*-(2-(4-Chlorophenyl)-4-oxoquinazolin-3(4H)-yl)-2-(4-(2-((3,5-dimethylphenyl)amino)-acetyl)piperazin-1-yl)acetamideIR: 1669 (C=O str., CONH~2~), 3213 (N--H str., 2° NH~2~), 1467 (N--N str.), 1253 (C--N str.), 3066 (C--H str., Ar), 1588 (C=C str., Ar), 1634 (C= N str., Ar), 2957 (C--H str., R-CO--CH~2~), 1726 (C=O str., Ar-ketone), 725 (C--Cl str., Ar--Cl), 2862 (C--H sym str., Ar-CH~3~)^1^H-NMR: 7.55--7.86 (m, 11H, ArH), 8.19 (s, 1H, N--NH), 4.16 (d, 2H, CH~2~), 3.30 (t, 4H, CH~2~ of piperazine), 2.65 (t, 4H, CH~2~ of piperazine), 2.37 (s, 3H, CH~3~); ^13^C--NMR: 170.3, 164.9, 164.7, 161.2, 151.4, 143.4, 135.4, 133.3, 131.5, 129.7, 129.3, 128.3, 127.3, 127.0, 126.8, 126.6, 126.4, 126.3, 122.2, 120.4, 113.5, 58.9, 53.8, 52.1, 52.0, 46.9, 46.4, 24.7, 15.6Anal cal. C, 64.45; H, 5.59; N, 15.03; Found: C, 64.47; H, 5.56; N, 15.05; MS ES+ (ToF): *m/z* 560 \[M^+^ + 1\]**5.***N*-(2-(4-Chlorophenyl)-4-oxoquinazolin-3(4H)-yl)-2-(4-(2-((3,4-dichlorophenyl)-amino)acetyl)piperazin-1-yl)acetamideIR: 1665 (C=O str., CONH~2~), 3216 (N--H str., 2° NH~2~), 1463 (N--N str.), 1252 (C--N str.), 3056 (C--H str., Ar), 1591 (C=C str., Ar), 1611 (C= N str., Ar), 2923 (C--H str., R-CO--CH~2~), 1709 (C=O str., Ar-ketone), 724 (C--Cl str., Ar--Cl)^1^H-NMR: 6.72--7.86 (m, 11H, ArH), 8.19 (s, 1H, N--NH), 4.15 (d, 2H, CH~2~), 3.32 (t, 4H, CH~2~ of piperazine), 2.64 (t, 4H, CH~2~ of piperazine); ^13^C--NMR: 170.5, 164.9, 164.7, 161.5, 151.3, 145.6, 135.0, 134.3, 133.2, 129.8, 129.4, 129.2, 128.5, 127.5, 127.1, 126.6, 123.2, 122.5, 120.7, 118.9, 113.1, 58.8, 52.8, 52.4, 46.3, 46.8Anal cal. C, 56.06; H, 4.20; N, 14.01; Found: C, 56.06; H, 4.20; N, 14.01; MS ES+ (ToF): *m/z* 600 \[M^+^ + 1\]**6.***N*-(2-(4-Chlorophenyl)-4-oxoquinazolin-3(4H)-yl)-2-(4-(2-((3-methyl-4-nitrophenyl)-amino)acetyl)piperazin-1-yl)acetamideIR: 1669 (C=O str., CONH~2~), 3211 (N--H str., 2° NH~2~), 1474 (N--N str.), 1251 (C--N str.), 1590 (C=C str., Ar), 1634 (C= N str., Ar), 2928 (C--H str., R-CO--CH~2~), 1729 (C=O str., Ar-ketone), 725 (C--Cl str., Ar--Cl), 2862 (C--H sym str., Ar-CH~3~), 1559 (NO~2~ asym str.)^1^H-NMR: 6.45--8.05 (m, 11H, ArH), 8.19 (s, 1H, N--NH), 4.15 (d, 2H, CH~2~), 3.33 (t, 4H, CH~2~ of piperazine), 2.63 (t, 4H, CH~2~ of piperazine), 3.54 (s, 3H, OCH~3~); ^13^C--NMR: 170.6, 164.6, 164.4, 161.1, 152.7, 151.5, 136.8, 135.2, 133.4, 129.6, 129.4, 128.3, 127.4, 127.3, 126.3, 125.2, 122.7, 120.9, 118.6, 114.5, 58.5, 53.5, 52.5, 46.9, 46.0, 52.5, 14.3Anal cal. C, 57.47; H, 4.66; N, 16.18; Found: C, 57.46; H, 4.68; N, 16.19; MS ES+ (ToF): *m/z* 591 \[M^+^ + 1\]**7.***N*-(2-(4-Chlorophenyl)-4-oxoquinazolin-3(4H)-yl)-2-(4-(2-((3-nitrophenyl)amino)-acetyl)piperazin-1-yl)acetamideIR: 1668 (C=O str., CONH~2~), 3213 (N--H str., 2° NH~2~), 1467 (N--N str.), 1253 (C--N str.), 3066 (C--H str., Ar), 1588 (C=C str., Ar), 1632 (C= N str., Ar), 2958 (C--H str., R-CO--CH~2~), 1727 (C=O str., Ar-ketone), 725 (C--Cl str., Ar--Cl), 1558 (NO~2~ asym str.)^1^H-NMR: 6.73--7.85 (m, 12H, ArH), 8.19 (s, 1H, N--NH), 4.16(d, 2H, CH~2~), 3.32 (t, 4H, CH~2~ of piperazine), 2.63 (t, 4H, CH~2~ of piperazine); ^13^C--NMR: 170.5, 164.5, 164.2, 161.0, 151.6, 149.4, 148.3, 135.5, 133.5, 130.8, 129.3, 129.0, 128.5, 127.6, 127.2, 127.1, 126.3, 122.8, 120.7, 119.4, 107.6, 109.7, 58.3, 53.0, 52.6, 52.3, 46.8, 46.2Anal cal. C, 58.39; H, 4.55; N, 17.02; Found: C, 58.42; H, 4.56; N, 17.01; MS ES+ (ToF): *m/z* 577 \[M^+^ + 1\]**8.***N*-(2-(4-Chlorophenyl)-4-oxoquinazolin-3(4H)-yl)-2-(4-(2-((4-chlorophenyl)amino)- acetyl)-piperazin-1-yl)acetamideIR: 1667 (C=O str., CONH~2~), 3214 (N--H str., 2° NH~2~), 1469 (N--N str.), 1250 (C--N str.), 3067 (C--H str., Ar), 1592 (C=C str., Ar), 1630 (C= N str., Ar), 2958 (C--H str., R-CO--CH~2~), 1720 (C=O str., Ar-ketone), 725 (C--Cl str., Ar--Cl), 2862 (C--H sym str., Ar-CH~3~)^1^H-NMR: 6.09--8.03 (m, 12H, ArH), 8.19 (s, 1H, N--NH), 4.15 (d, 2H, CH~2~), 3.31 (t, 4H, CH~2~ of piperazine), 2.66 (t, 4H, CH~2~ of piperazine); ^13^C--NMR: 170.2, 164.6, 164.2, 161.4, 151.7, 149.3, 135.6, 135.4, 131.2, 133.1, 129.5, 129.3, 128.8, 127.4, 127.2, 126.6, 122.5, 120.5, 117.5, 113.6, 111.7, 58.5, 52.7, 52.5, 53.5, 46.9, 46.5Anal cal. C, 59.47; H, 4.63; N, 14.86; Found: C, 59.43; H, 4.68; N, 14.88; MS ES+ (ToF): *m/z* 565 \[M^+^ + 1\]**9.***N*-(2-(4-Chlorophenyl)-4-oxoquinazolin-3(4H)-yl)-2-(4-(2-((2-methyl-5-nitrophenyl) amino)-acetyl)piperazin-1-yl)acetamideIR: 1668 (C=O str., CONH~2~), 3213 (N--H str., 2° NH~2~), 1468 (N--N str.), 3068 (C--H str., Ar), 1589 (C=C str., Ar), 1631 (C= N str., Ar), 2957 (C--H str., R-CO--CH~2~), 1726 (C=O str., Ar-ketone), 725 (C--Cl str., Ar--Cl), 1252 (C--N str., piperazine), 1558 (NO~2~ asym str.)^1^H-NMR: 7.16--7.74 (m, 11H, ArH), 8.19 (s, 1H, N--NH), 4.15(d, 2H, CH~2~), 3.33 (t, 4H, CH~2~ of piperazine), 2.63 (t, 4H, CH~2~ of piperazine), 2.38 (s, 3H, CH~3~); ^13^C--NMR: 170.5, 164.4, 164.0, 161.2, 151.6, 147.5, 146.5, 135.7, 133.0, 132.6, 130.9, 129.6, 129.5, 128.5, 127.6, 127.5, 127.1, 126.9, 122.4, 120.3, 109.7, 107.5, 58.7, 53.4, 52.9, 52.6, 46.8, 46.6, 15.7Anal cal. C, 59.03; H, 4.78; N, 16.62; Found: C, 59.01; H, 4.74; N, 16.60; MS ES+ (ToF): *m/z* 591 \[M^+^ + 1\]**10.***N*-(2-(4-Chlorophenyl)-4-oxoquinazolin-3(4H)-yl)-2-(4-(2-((4-methoxyphenyl) amino)acetyl)-piperazin-1-yl)-acetamideIR: 1670 (C=O str., CONH~2~), 3215 (N--H str., 2° NH~2~), 1470 (N--N str.), 1250 (C--N str.), 3065 (C--H str., Ar), 1591 (C=C str., Ar), 1635 (C= N str., Ar), 1776 (C=O str., Ar-ketone), 725 (C--Cl str., Ar--Cl), 2892 (C--H str., R-CO--CH~2~), 1195 (C--O--C str., Ar--O--CH~3~)^1^H-NMR: 7.55--7.88 (m, 12H, ArH), 8.19 (s, 1H, N--NH), 4.15(d, 2H, CH~2~), 3.33 (t, 4H, CH~2~ of piperazine), 2.64 (t, 4H, CH~2~ of piperazine), 3.71 (s, 3H, OCH~3~); ^13^C--NMR: 170.5, 164.3, 161.2, 151.5, 149.4, 139.7, 135.9, 133.4, 129.4, 129.3, 128.7, 127.8, 127.7, 127.6, 126.6, 122.7, 120.8, 115.3, 115.2, 114.7, 114.6, 58.9, 55.4, 53.6, 52.7, 52.5, 46.7, 46.6Anal cal. C, 62.08; H, 5.21; N, 14.98; Found: C, 62.09; H, 5.25; N, 14.99; MS ES+ (ToF): *m/z* 562 \[M^+^ + 1\]**11.***N*-(2-(4-Chlorophenyl)-4-oxoquinazolin-3(4H)-yl)-2-(4-(2-((2-chlorophenyl)amino)-acetyl)piperazin-1-yl)acetamideIR: 3177 (N--H str., 2° NH~2~), 1500 (N--N str.), 1247 (C--N str.), 3096 (C--H str., Ar), 1598 (C=C str., Ar), 1634 (C= N str., Ar), 2958 (C--H str., R-CO--CH~2~), 1725 (C=O str., Ar-ketone), 722 (C--Cl str., Ar--Cl)^1^H-NMR: 7.22--7.71 (m, 11H, ArH), 8.19 (s, 1H, N--NH), 4.15(d, 2H, CH~2~), 3.31 (t, 4H, CH~2~ of piperazine), 2.65 (t, 4H, CH~2~ of piperazine); ^13^C--NMR: 170.5, 164.8, 164.2, 161.0, 151.3, 150.1, 138.4, 135.5, 133.2, 129.3, 129.1, 128.4, 127.7, 127.4, 127.3, 126.9, 122.6, 124.7, 123.5, 120.3, 120.1, 115.6, 58.6, 52.9, 52.7, 52.5, 46.6, 46.2Anal cal. C, 55.09; H, 4.13; N, 16.06; Found: C, 55.06; H, 4.17; N, 16.09; MS ES+ (ToF): *m/z* 566 \[M^+^ + 1\]**12.**2-(4-(2-((2-Chloro-4-nitrophenyl)amino)acetyl)piperazin-1-yl)-*N*-(2-(4-chloro-phenyl)-4-oxoquinazolin-3(4H)-yl)acetamideIR: 1669 (C=O str., CONH~2~), 3214 (N--H str., 2° NH~2~), 1479 (N--N str.), 1251 (C--N str.), 3071 (C--H str., Ar), 1591 (C=C str., Ar), 1636 (C= N str., Ar.), 2958 (C--H str., R-CO--CH~2~), 1726 (C=O str., Ar-ketone), 724 (C--Cl str., Ar--Cl)^1^H-NMR: 6.60--7.85 (m, 11H, ArH), 8.19 (s, 1H, N--NH), 4.16(d, 2H, CH~2~), 3.31 (t, 4H, CH~2~ of piperazine), 2.65 (t, 4H, CH~2~ of piperazine); ^13^C--NMR: 170.6, 164.5, 164.3, 161.4, 151.5, 149.7, 146.7, 135.6, 133.4, 130.7, 129.6, 129.3, 128.5, 127.9, 127.5, 127.1, 126.7, 122.7, 121.2, 120.3, 117.5, 108.9, 58.8, 53.6, 52.9, 52.8, 46.7, 46.4Anal cal. C, 55.09; H, 4.13; N, 16.06; Found: C, 55.07; H, 4.17; N, 16.03; MS ES+ (ToF): *m/z* 611 \[M^+^ + 1\]**13.***N*-(2-(4-Chlorophenyl)-4-oxoquinazolin-3(4H)-yl)-2-(4-(2-(phenylamino)acetyl) piperazin-1-yl)acetamideIR: 1668 (C=O str., CONH~2~), 3214 (N--H str., 2° NH~2~), 1468 (N--N str.), 1251 (C--N str.), 3067 (C--H str., Ar), 1590 (C=C str., Ar), 1631 (C= N str., Ar), 2928 (C--H str., R-CO--CH~2~), 1725 (C=O str., Ar-ketone), 725 (C--Cl str., Ar--Cl)^1^H-NMR: 6.50--7.73 (m, 13H, ArH), 8.19 (s, 1H, N--NH), 4.19 (d, 2H, CH~2~), 3.31 (t, 4H, CH~2~ of piperazine), 2.65 (t, 4H, CH~2~ of piperazine); ^13^C--NMR: 170.9, 164.7, 164.0, 161.5, 151.7, 147.8, 135.9, 133.1, 129.9, 129.6, 129.4, 129.2, 128.3, 127.6, 127.5, 127.2, 126.4, 122.9, 120.6, 117.5, 113.6, 113.3, 58.9, 53.4, 52.8, 52.4, 46.9, 46.6Anal cal. C, 63.33; H, 5.13; N, 15.83; Found: C, 63.38; H, 5.17; N, 15.81; MS ES+ (ToF): *m/z* 632 \[M^+^ + 1\]**14.***N*-(2-(4-Chlorophenyl)-4-oxoquinazolin-3(4H)-yl)-2-(4-(2-((2,4-dichlorophenyl)amino)-acetyl)piperazin-1-yl)acetamideIR: 1668 (C=O str., CONH~2~), 3213 (N--H str., 2° NH~2~), 1467 (N--N str.), 1274 (C--N str.), 3066 (C--H str., Ar), 1592 (C=C str., Ar), 1632 (C= N str., Ar), 2928 (C--H str., R-CO--CH~2~), 1726 (C=O str., Ar-ketone), 726 (C--Cl str., Ar--Cl)^1^H-NMR: 6.35--7.69 (m, 11H, ArH), 8.19 (s, 1H, N--NH), 4.15 (d, 2H, CH~2~), 3.32 (t, 4H, CH~2~ of piperazine), 2.65 (t, 4H, CH~2~ of piperazine); ^13^C--NMR: 170.6, 164.8, 164.1, 161.8, 151.4, 147.4, 135.8, 134.3, 133.0, 131.4, 129.2, 129.0, 128.7, 127.5, 127.4, 127.3, 126.7, 122.6, 121.7, 120.7, 115.5, 113.2, 58.5, 53.5, 52.5, 52.2, 46.8, 46.5Anal cal. C, 56.06; H, 4.20; N, 14.01; Found: C, 56.08; H, 4.22; N, 14.04; MS ES+ (ToF): *m/z* 601 \[M^+^ + 1\]**15.***N*-(2-(4-Chlorophenyl)-4-oxoquinazolin-3(4H)-yl)-2-(4-(2-((3,5-dichlorophenyl)amino)-acetyl)piperazin-1-yl)acetamideIR: 1668 (C=O str., CONH~2~), 3214 (N--H str., 2° NH~2~), 1468 (N--N str.), 1251 (C--N str.), 3072 (C--H str., Ar), 1591 (C=C str., Ar), 1632 (C=N str., Ar), 2956 (C--H str., R-CO--CH~2~), 1725 (C=O str., Ar-ketone), 725 (C--Cl str., Ar--Cl)^1^H-NMR: 7.55--7.86 (m, 12H, ArH), 8.19 (s, 1H, N--NH), 4.14 (d, 2H, CH~2~), 3.31 (t, 4H, CH~2~ of piperazine), 2.64 (t, 4H, CH~2~ of piperazine); ^13^C--NMR: 170.4, 164.6, 164.0, 161.5, 151.1, 143.7, 135.5, 133.2, 129.8, 129.2, 129.0, 128.4, 127.7, 127.6, 127.5, 127.3, 126.9, 122.3, 122.5, 120.8, 118.4, 114.5, 58.3, 52.7, 52.4, 52.3, 46.9, 46.7Anal cal. C, 59.47; H, 4.63; N, 14.86; Found: C, 59.49; H, 4.61; N, 14.87; MS ES+ (ToF): *m/z* 601 \[M^+^ + 1\]**16.***N*-(2-(4-Chlorophenyl)-4-oxoquinazolin-3(4H)-yl)-2-(4-(2-((4-nitrophenyl)amino)acetyl)-piperazin-1-yl)acetamideIR: 1669 (C=O str., CONH~2~), 3217 (N--H str., 2° NH~2~), 1469 (N--N str.), 1254 (C--N str.), 3077 (C--H str., Ar), 1561 (C=C str., Ar), 1629 (C= N str., Ar), 2958 (C--H str., R-CO--CH~2~), 1726 (C=O str., Ar-ketone), 725 (C--Cl str., Ar--Cl), 1561 (NO~2~ asym str.)^1^H-NMR: 6.43--7.76 (m, 12H, ArH), 8.19 (s, 1H, N--NH), 4.14 (d, 2H, CH~2~), 3.31 (t, 4H, CH~2~ of piperazine), 2.63 (t, 4H, CH~2~ of piperazine); ^13^C--NMR: 170.7, 164.8, 164.3, 161.6, 153.8, 151.5, 136.6, 135.6, 133.0, 129.3, 129.1, 128.2, 127.8, 127.5, 127.4, 126.8, 122.1, 121.7, 120.9, 114.6, 114.5, 58.4, 53.2, 52.4, 52.2, 46.9, 46.6Anal cal. C, 58.39; H, 4.55; N, 17.02; Found: C, 58.40; H, 4.57; N, 17.04; MS ES+ (ToF): *m/z* 577 \[M^+^ + 1\]**17.***N*-(2-(4-Chlorophenyl)-4-oxoquinazolin-3(4H)-yl)-2-(4-(2-((2-nitrophenyl)amino)acetyl)-piperazin-1-yl)acetamideIR: 1668 (C=O str., CONH~2~), 3213 (N--H str., 2° NH~2~), 1467 (N--N str.), 1253 (C--N str.), 3067 (C--H str., Ar), 1590 (C=C str., Ar), 1632 (C= N str., Ar), 2957 (C--H str., R-CO--CH~2~), 1726 (C=O str., Ar-ketone), 726 (C--Cl str., Ar--Cl), 1559 (NO~2~ asym str.)^1^H-NMR: 6.63--7.76 (m, 12H, ArH), 8.19 (s, 1H, N--NH), 4.17 (d, 2H, CH~2~), 3.32 (t, 4H, CH~2~ of piperazine), 2.51 (t, 4H, CH~2~ of piperazine); ^13^C--NMR: 170.9, 164.9, 164.6, 161.3, 151.9, 138.4, 135.8, 135.5, 133.5, 132.3, 129.5, 129.4, 128.0, 127.9, 127.6, 127.4, 126.9, 122.4, 121.7, 120.6, 118.3, 114.6, 58.7, 52.5, 52.4, 52.3, 46.8, 46.7Anal cal. C, 58.39; H, 4.55; N, 17.02; Found: C, 58.37; H, 4.51; N, 17.01; MS ES+ (ToF): *m/z* 577 \[M^+^ + 1\]

Antimicrobial screening results {#Sec18}
-------------------------------

The synthesized compounds were tested by tube dilution technique against Gram positive and Gram negative bacterial and fungal strains for their in vitro antimicrobial activity and the MIC values of control drugs and synthetic compounds are shown in Table [3](#Tab3){ref-type="table"}. Antimicrobial screening results indicated that compound **3** (MIC~bs~ = 4.81 µM) emerged as most effective antibacterial agent toward *B. subtilis.* Compounds **11** and **12** (MIC~sa~ = 2.56 µM**)** displayed the promising activity toward *S. aureus.* Compound **8** (MIC~ec~ = 5.54 µM) emerged as most active candidate against Gram-negative bacterium *E. coli* and comparable to standard drug ciprofloxacin. In the case of antifungal activity, compound **3** (MIC~ca~ = 4.81 and MIC~an~ = 2.40 µM) was found to be the most potent antifungal agent against *C. albicans* and *A. niger* and had better antifungal activity than standard drug fluconazole (MIC~ca,an~ = 5.09 µM). Results of antimicrobial activity indicated that the synthesized compounds possessed a higher antifungal activity than antibacterial activity. As far as antibacterial activity is concerned, the synthesized compounds were more active against Gram negative bacterium (*E. coli*) than Gram positive bacteria (*S. aureus* and *B. subtilis*).Table 3Antimicrobial screening results of the synthesized compoundsCompound no.Minimum inhibitory concentration (MIC = µM)Bacterial strainsFungal strains*B. subtilisS. aureusE. coliC. albicansA. niger***1.**91.7411.4722.9411.4791.74**2.**22.1288.5011.0622.1211.06**3.**4.8119.239.624.812.40**4.**22.3611.1889.4511.1889.45**5.**83.4710.4383.4710.4320.87**6.**21.1921.1921.1910.595.30**7.**21.7010.8586.8110.8586.81**8.**22.1611.085.5488.6511.08**9.**10.5921.1984.7510.5921.19**10.**11.1422.2889.1389.1311.14**11.**20.492.5620.4910.2581.97**12.**81.972.5681.9720.495.12**13.**11.7723.5411.7723.5494.16**14.**10.4320.8783.4720.8783.47**15.**83.3383.3310.4220.8320.83**16.**86.8110.8586.8110.8521.70**17.**21.7086.8121.7010.8521.70Std.4.71^a^4.71^a^4.71^a^5.09^b^5.09^b^DMSONANANANANABroth controlNGNGNGNGNGThe samples were incubated at 37 ± 1 °C for 24 h (bacteria), at 25 ± 1 °C for 7d (*A. niger*) and at 37 ± 1 °C for 48 h (*C. albicans*), respectively and the results were recorded in terms of MIC (the lowest concentration of test substance which inhibited the growth of microorganisms)Std.: ^a^Ciprofloxacin, ^b^Fluconazole; *NA* no activity, *NG* no growth

Anticancer screening results {#Sec19}
----------------------------

The synthesized compounds were evaluated for their in vitro anticancer activity against human colorectal cancer (HCT116) and mouse monocyte macrophage (RAW 264.7) cancer cell lines using MTT assay. Compound **5** (IC~50~ = 0.82 and 12.39 µM against RAW 264.7 and HCT116, respectively) was found to be the most active one and compared to the 5-fluorouracil and Tomudex (used as standard drugs). The anticancer screening (IC~50~ = µM) results are shown in Table [4](#Tab4){ref-type="table"}.Table 4Anticancer screening results of the synthesized compoundsCompound no.Anticancer screening (IC~50~ = µM)Cancer cell linesHCT116RAW 264.7**1**.119.261.30**2.**93.733.36**3.**91.781.95**4.**20.278.53**5.**12.390.82**6.**27.125.08**7.**24.311.20**8.**99.2714.36**9.**103.3815.93**10.**52.284.63**11.**114.6716.38**12.**81.913.06**13.**94.1417.70**14.**87.2326.67**15.**84.8917.45**16.**30.099.55**17.**14.641.74Raltitrexed (Tomudex)9.052.815-Fluorouracil4.600.60

Molecular docking results {#Sec20}
-------------------------

The synthesized derivatives of quinazolinone showed excellent docking performance and the chosen proteins were discovered to communicate with significant amino acids. Molecular docking was performed to analyze the binding mode of active compounds **5** and **7** for the cancer cell lines of human colorectal carcinoma (HCT116) and mouse leukaemic monocyte macrophage (RAW 264.7). The compound **5** and standard drugs (5-fluorouracil and tomudex) were docked in the active site of the cycline-dependent kinase cdk8 (PDB ID: 5FGK) co-crystallized acuity 5XG ligand and in the active site of the S121P murine COX-2 mutant (PDB ID: 5JVY) co-crystallized acuity ligand COH were also docked. The binding mode of native ligand 5XG have docked score   (− 8.72) and COH ligand have docked score (− 8.93) showed good interaction with crucial amino acids residues with their respective proteins (Fig. [3](#Fig3){ref-type="fig"}). The binding mode of compound **5** (Fig. [4](#Fig4){ref-type="fig"}) (using PDB ID: 5FGK for HCT116), scored docked score (− 8.011) with moderate anticancer potency (12.39 μM) and formed H-bond with crucial amino acids and compared to the docked score of 5-fluorouracil (Fig. [5](#Fig5){ref-type="fig"}) have lowest docked score (− 5.753) with better anticancer activity (4.6 μM) and tomudex (− 10.86) have good docked score with better anticancer potency (9.05 μM) (Fig. [6](#Fig6){ref-type="fig"}a). The binding mode of active compound **5** (using PDB ID: 5JVY for mouse leukaemic monocyte macrophage) have docked score (− 11.054) with better anticancer activity (0.82 μM) which also developed H-bond with crucial amino acid (Fig. [7](#Fig7){ref-type="fig"}) and compound **7** have docked score (− 11.284) with better anticancer potency (1.20 μM) (Fig. [8](#Fig8){ref-type="fig"}) and comparable to 5-fluorouracil have lowest docked score (− 4.122) with better anticancer potency (0.60 μM) (Fig. [9](#Fig9){ref-type="fig"}) and also compared to the tomudex (− 10.83) have better docked score with better anticancer potency (2.81 μM) (Fig. [6](#Fig6){ref-type="fig"}b). The docking results of synthesized compounds (**5** and **7**), native ligands and standard drug (tomudex) which showed good to better docking score with their respective proteins. Docking results and interacting residues are shown in Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}.Fig. 3Binding surface and ligand interaction diagram of native ligand 5XG (**a**) and COH (**b**) with their respective protein Fig. 4Binding surface and ligand interaction diagram of compound **5** Fig. 5Binding surface and ligand interaction diagram of 5-fluorouracil Fig. 6Binding surface and ligand interaction diagram of Raltitrexed (Tomudex) with 5FGK (**a**) and 5JVY (**b**) proteins Fig. 7Binding surface and ligand interaction diagram of compound **5** Fig. 8Binding surface and ligand interaction diagram of compound **7** Fig. 9Binding surface and ligand interaction diagram of 5-fluorouracil Table 5Molecular docking results and interacting residues of compound **5** and standard drugsCompound no.Docking scoreGlide energy (kcal/mol)Interacting residues**5**− 8.011− 64.796Ala155, Leu158, Ile79, Ala172, Asp173, Phe176, VaL35, Tyr32, Glu66, Lys52, Ala50, Phe97, Asp98, Tyr99, Ala100, Asp103, Trp105, Hid106, Arg356, Glu357, Leu359, Val275XG− 8.72− 49.49Ile79, Ala172, Asp173, Arg356, Phe97, Ala 100, Val159, Glu101, Gly33Raltitrexed (Tomudex)− 10.86− 54.30Met174, Asp173, Phe176, Glu66A, Lys52, Leu70, Ile795-Fluorouracil− 5.753− 21.673Leu158, Arg356, Ala100, Tyr99, Asp98, Phe97, Ile79, Ala50, Val35 Table 6Molecular docking results and interacting residues of compounds **5, 7** and standard drugsCompound no.Docking scoreGlide energy (kcal/mol)Interacting residues**5**− 11.054− 68.766Gln455, Ser452, Ala451, Val448, Val445, Asn383, Tyr386, Hie387, Trp388, Hie389, Leu391, Leu392, Phe396, Phe405, Val296, Leu295, Phe201, Ala203, Gln204, Thr207, His208, Phe211, Lys212, Thr213, Hie215, Tyr149, Leu409**7**− 11.284− 71.663Phe405, Phe396, Leu392, Leu391, Hie389, Trp388, Hie387, Tyr386, Tyr149, Asn383, Leu409, Ala200, Phe201, Ala203, Gln204, Thr207, His208, Phe211, Lys212, Thr213, Asp214, Hie215, Val296, Leu295, Val292, Glu291, Gln290, Ile275, Arg223, Val448COH− 8.93− 54.81Glu291, Lys216, Arg223, Lys212, Gln290, His 215Raltitrexed (Tomudex)− 10.83− 58.73Glu291, Arg223, Lys212, Gln290, Thr238, Glu 2095-Fluorouracil− 4.122− 26.585Leu392, Leu391, Hie389, Trp388, Hie387, Tyr386, Thr207, Gln204, Ala203, Ala200

The docking findings therefore indicate that the synthesized compounds may be of excellent importance in effective chemotherapy. The selected database of protein i.e. (PDB ID: 5FGK) for human colorectal carcinoma and (PDB ID: 5JVY) mouse monocyte macrophage may be the target protein of derivatives of quinazolinone for their anticancer activity (Additional file [3](#MOESM3){ref-type="media"}).

Structure activity relationship studies (SAR) {#Sec21}
=============================================

The SAR of synthesized compounds can be summarized (Fig. [10](#Fig10){ref-type="fig"}) as follow:Fig. 10Structure activity relationship study of the synthesized compounds Results of antimicrobial activity indicated that substitution of phenyl amino ring attached to the chlorophenyl quinazolinone piperazine-acetamide nucleus with electron donating methyl group enhanced the antimicrobial activity against *B. subtilis, C. albicans* and *A. niger.*In the case of antibacterial activity towards *S. aureus* and *E. coli,* electron withdrawing groups i.e. chloro (Cl) and chloro with nitro (NO~2~) substitution on the phenylamino ring attached to the chlorophenyl quinazolinone piperazine-acetamide nucleus increased the antibacterial activity.Results of anticancer activity revealed that the presence of electron withdrawing groups i.e. dichloro on the phenylamino ring attached to the chlorophenyl quinazolinone piperazine acetamide nucleus increased the anticancer activity against both cancer cell lines (RAW 264.7 and HCT116).

Conclusion {#Sec22}
==========

In the present study, the synthesized quinazolinone derivatives i.e. compound **3** showed promising antimicrobial activity due to the presence of electron releasing group at *meta*--position of the substituted benzylidene nucleus and comparable to the control drugs. In case of anticancer activity indicated that compound **5** (*meta/para*-Cl) and compound **7** (*meta-*NO~2~) displayed moderate anticancer activity towards human colorectal carcinoma and mouse leukaemic monocyte macrophage cancer cell lines due to the presence of EWG on the substituted benzylidene nucleus. Molecular docking analysis demonstrated that compounds **5** and **7** showed the better docked score with better potency and comparable to the standard drug and native ligands of the proteins. The findings of the docking are compatible with the assays of anticancer. Docking information stay in excellent correlation with the outcomes of anticancer activity and these molecules may be used as a lead in the design of new anticancer agents.

Supplementary information
=========================

 {#Sec23}

**Additional file 1.** Web link for PDB ID: 5FGK and 5JVY proteins. **Additional file 2.** Synthetic scheme with chemical structures. **Additional file 3.** Docking results of active compounds.
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